ASLAN Pharmaceuticals Announces Closing of US$15 Million Public Offering of American Depositary Shares, Including Full Exerci...
December 05 2019 - 06:22PM
ASLAN Pharmaceuticals Limited (Nasdaq:ASLN, TPEx:6497), a
clinical-stage oncology and immunology focused biopharma company,
today announced the closing of its previously announced
underwritten public offering of 5,893,206 American Depositary
Shares (“ADSs”) at a public offering price of US$2.50 per ADS,
including the exercise in full of the underwriter’s option to
purchase additional ADSs. Each ADS represents five ordinary shares
of ASLAN. The gross proceeds to ASLAN, before deducting
underwriting discounts, commissions and other offering expenses,
were approximately US$14.7 million. The aggregate offering amount,
including the underwriter’s option, reflects the maximum market
value of securities that ASLAN is allowed to sell under “baby
shelf” rules currently applicable to its effective shelf
registration statement on Form F-3.
H.C. Wainwright & Co. acted as sole
book-running manager for the offering.
The securities described above were offered by
ASLAN pursuant to a shelf registration statement on Form F-3,
including a base prospectus, that was previously filed by ASLAN
with the Securities and Exchange Commission (the “SEC”)
and that was declared effective on November 8, 2019. A final
prospectus supplement and accompanying prospectus relating to the
offering was also filed with the SEC and is available for
free on the SEC’s website located at http://www.sec.gov. An
electronic copy of the final prospectus supplement and the
accompanying prospectus relating to the offering may also be
obtained from H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd
Floor, New York, NY 10022, by calling (646) 975-6996 or emailing
placements@hcwco.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497)
is a clinical-stage oncology and immunology focused biopharma
company targeting diseases that are either more prevalent in Asia,
where the availability of suitable patients is greater or there are
fewer competing studies. Led by a senior management team with
extensive experience in global and regional development and
commercialisation, ASLAN is headquartered in Singapore and has a
clinical portfolio comprised of one monoclonal antibody therapy
targeting inflammatory disease and two small molecule inhibitors
targeting oncology. ASLAN’s partners include Array BioPharma,
Bristol-Myers Squibb, Almirall and CSL. For additional information
please visit www.aslanpharma.com.
Media contact
Emma Thompson
Spurwing Communications
Tel: +65 6571 2021
Email: ASLAN@spurwingcomms.com
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
From Feb 2024 to Mar 2024
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
From Mar 2023 to Mar 2024